Table 2. Disease-free survival and disease-specific survival according to SLC2A1 expression in 279 patients with gastric cancer (Eulji Hospital cohort).

Disease-free survival	Univariate1	Multivariate2	HR	95% CI
SLC2A1 (low vs. high)	0.041	0.283	0.689	0.350	1.359
T stage (1 or 2 vs. 3 or 4)	<0.001	0.088	2.167	0.892	5.268
N stage (0 vs. 1, 2 or 3)	<0.001	<0.001	6.950	2.707	17.843
Histological grade (1 or 2 vs. 3)	0.442	0.111	0.596	0.315	1.126
Vascular invasion (absence vs. presence)	<0.001	0.005	2.451	1.303	4.612
Perineural invasion (absence vs. presence)	<0.001	0.087	1.756	0.922	3.345
Disease-specific survival	Univariate1	Multivariate2	HR	95% CI
SLC2A1 (low vs. high)	<0.001	0.005	2.543	1.330	4.865
T stage (1 or 2 vs. 3 or 4)	<0.001	0.025	2.535	1.125	5.713
N stage (0 vs. 1, 2 or 3)	<0.001	0.02	2.438	1.151	5.163
Histological grade (1 or 2 vs. 3)	0.145	0.536	1.194	0.682	2.089
Vascular invasion (absence vs. presence)	<0.001	0.362	1.320	0.727	2.397
Perineural invasion (absence vs. presence)	<0.001	0.369	1.316	0.723	2.395

HR, hazard ratio; CI, confidence interval.

1Log rank test.

2Cox proportional hazard model.

p < 0.05 is shown in bold.